Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis
2011

Cancer Risk in Women with Systemic Lupus Erythematosus

Sample size: 47325 publication Evidence: high

Author Information

Author(s): Sasha Bernatsky, Ramsey-Goldman R, Foulkes W D, Gordon C, Clarke A E

Primary Institution: McGill University Health Centre

Hypothesis

What is the risk of breast, ovarian, and endometrial cancers in women with systemic lupus erythematosus compared to the general population?

Conclusion

Women with systemic lupus erythematosus have a decreased risk of breast, ovarian, and endometrial cancers.

Supporting Evidence

  • The total number of cancers observed was less than that expected.
  • SIRs for breast, endometrial, and ovarian cancers were 0.76, 0.71, and 0.66 respectively.
  • Data suggest that inherent differences in women with SLE may contribute to the decreased cancer risk.

Takeaway

Women with a disease called lupus are less likely to get certain types of cancers compared to other women.

Methodology

Data were included from five recent studies of large SLE cohorts, and the standardized incidence ratio (SIR) was calculated for observed versus expected cancers.

Potential Biases

Potential bias due to varying cancer profiles influenced by race and the inclusion of patients with previous cancer histories.

Limitations

The study did not stratify cancer risk by race and did not include wash-out periods.

Participant Demographics

The cohort included 47,325 SLE patients, with 42,171 being female.

Statistical Information

Confidence Interval

{"breast_cancer":"95% CI: 0.69, 0.85","endometrial_cancer":"95% CI: 0.55, 0.91","ovarian_cancer":"95% CI: 0.49, 0.90"}

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/bjc.2011.115

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication